Development of rapid genotyping methods for single nucleotide polymorphisms of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 2C19 (CYP2C19) and their clinical application in pediatric patients with epilepsy

Yakugaku Zasshi

Volumn 131, Issue 5, 2011, Pages 809-815

  Yamamoto, Yoshiaki ^a,b   Takahashi, Yukitoshi ^a   Nishimura, Shigeko ^a   Ikumi, Yasuhiro ^a   Mishima, Nobuyuki ^a   Kagawa, Yoshiyuki ^b  

^a SHIZUOKA INSTITUTE OF EPILEPSY AND NEUROLOGICAL DISORDERS   (Japan)

^b UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Cytochrome P450 2C19 (CYP2C19); Cytochrome P450 2C9 (CYP2C9); Epilepsy; Genotyping method; Light Cycler

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; PHENYTOIN;

CLINICAL ARTICLE; DRUG METABOLISM; EPILEPSY; GENOTYPE; HUMAN; NOTE; PEDIATRICS; POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ANTICONVULSANTS; ARYL HYDROCARBON HYDROXYLASES; CHILD, PRESCHOOL; EPILEPSY; FEMALE; GENOTYPING TECHNIQUES; HUMANS; INDIVIDUALIZED MEDICINE; INFANT; MALE; OVERDOSE; PHENYTOIN; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 79955731152     PISSN: 00316903     EISSN: 13475231     Source Type: Journal    
DOI: 10.1248/yakushi.131.809     Document Type: Note

References (15)

1. Shimono K., Nagai S., Jpn. J. Clin. Psychopharmacol., 10, 573-580 (2007).
2. Kiriono T., Ogata A., Shimodozono M., Nomoto Y., Kawahira K., Shigemi A., Jpn. J. Rehabil. Med., 45, 617-622 (2008).
3. Saito K., Shimizu K., Okazaki M., Ibayashi Y., Hashi K., Maeno K., Ishii S., Tuchihashi K., Shimamoto K., Toda T., Kurosawa N., Owada E., Kato Y., Oyama T., Umetu Y., Chida M., Ariyoshi N., Kamataki T., Itaya K., Jpn. J. Pharm. Health Care Sci., 27, 228-234 (2001).
4. Odani A., Hashimoto Y., Otsuki Y., Uwai Y., Hattori H., Furusho K., Inui K., Clin. Pharmacol. Ther., 62, 287-292 (1997).
5. Mamiya K., Ieiri I., Shimamoto J., Yukawa E., Imai J., Ninomiya H., Yamada H., Otsubo K., Higuchi S., Tashiro N., Epilepsia, 39, 1317-1323 (1998).
6. Yukawa E., Mamiya K., J. Clin. Pharm. Ther., 31, 275-282 (2006).
7. Mamiya K., Hadama A., Yukawa E., Ieiri I., Otsubo K., Ninomiya H., Tashiro N., Higuchi S., Eur. J. Clin. Pharmacol., 55, 821-825 (2000).
8. Kosaki K., Tamura K., Sato R., Samejima H., Tanigawara Y., Takahashi T., Brain Dev., 26, 530-534 (2004).
9. Kwiatkowski R. W., Lyamichev V., de Arruda M., Neri B., Mol. Diagn., 4, 353-364 (1999).
10. Takahashi Y., Japanese Unexamined Patent Application Publication No. 2009-278922 (2009.12.3).
11. Taguchi M., Hongou K., Yagi S., Miyawaki T., Takizawa M., Aiba T., Hashimoto Y., Drug Metab. Pharmacokinet., 20, 107-112 (2005).
12. Brandolese R., Scordo M. G., Spina E., Gusell M., Padrini R., Clin. Pharmacol. Ther., 70, 391-394 (2001).
13. Kidd R. S., Curry T. B., Gallagher S., Edeki T., Blaisdell J., Goldstein J. A., Pharmacogenetics, 11, 803-808 (2001).
14. Fujii J., Ikeda T., Higa Y., Seo T., Murata T., Nakagawa K., Maeda Y., Uchino M., Saito H., Jpn. J. Ther. Drug Monitor., 27, 136-139 (2010).
15. Seo T., Nagata R., Ishitsu T., Murata T., Takaishi C., Hori M., Nakagawa K., Pharmacogenomics, 9, 527-537 (2008).